Skip to content
Sora Lifesciences
France-based urology MedTech startup

Market opportunity for a novel PCNL endoscope

Delivered a comprehensive market opportunity assessment for an early-stage MedTech startup, enabling informed investment and commercialization decisions for a novel endoscope designed for PCNL procedures.

Key offerings in this project
  • Disease Epidemiology / Procedure Volume Estimation
  • Healthcare Infrastructure Mapping
  • Reimbursement Landscape & CMS Data Analytics

The brief

Case study for opportunity assessment of the US PCNL market

  • Estimate procedural volumes
  • Map clinical workflows
  • Assess reimbursement dynamics
  • Track adoption trends in kidney stone management

The client was a France-based startup developing innovative endoscopic technologies for urology applications.

The problem

Highly fragmented, limited and inconsistent data available in published literature specific to PCNL procedural economics and infrastructure

  • Estimate annual US PCNL volumes, benchmarked against URS and SWL
  • Map PCNL-performing urologists and facilities
  • Assess clinical practice and nephroscope usage
  • Evaluate reimbursement across all three procedures — pathways, coding and procedure economics

Published PCNL-specific figures disagreed with each other, so no single source could be taken at face value.

Our approach

Highly targeted secondary research and data triangulation, complemented by an in-depth KOL interview with an experienced urologist

  • Medicare datasets and CMS reimbursement databases (DRG, CPT, ICD)
  • Clinical literature, claims-based studies and urology society publications
  • Triangulation on physician-level data and retreatment rates
  • In-depth interview with a high-volume US urologist

The urologist interviewed performs roughly 120 PCNL procedures a year.

Key outcomes

Enabled the client to better assess commercial opportunity and future product positioning within the US stone management market

  • Comprehensive estimate of annual US PCNL volumes
  • Nephroscope market sized on replacement-cycle modelling
  • Rising adoption of Mini-PCNL and ambulatory, same-day-discharge procedures
  • Scope efficiency identified as the core unmet need

Of the two shifts, the move to same-day discharge proved the more consequential for positioning.

Related services

Get in touch

Facing a similar challenge?

Tell us what decision you're facing. We'll turn it into a clear, evidence-backed answer.

© 2026 Sora Life Sciences. All rights reserved.